These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37605297)

  • 1. Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve.
    Li C; Qiao Y; Jiang X; Liu L; Zheng Y; Qiu Y; Cheng C; Zhou F; Zhou Y; Huang W; Ren X; Wang Y; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2023 Sep; 66(17):12432-12445. PubMed ID: 37605297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
    Han X; Zhao L; Xiang W; Miao B; Qin C; Wang M; Xu T; McEachern D; Lu J; Wang Y; Metwally H; Yang CY; Kirchhoff PD; Wang L; Matvekas A; Takyi-Williams J; Wen B; Sun D; Ator M; Mckean R; Wang S
    J Med Chem; 2023 Jul; 66(13):8822-8843. PubMed ID: 37382562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIP5K1C phosphoinositide kinase deficiency distinguishes PIKFYVE-dependent cancer cells from non-malignant cells.
    Roy A; Chakraborty AR; Nomanbhoy T; DePamphilis ML
    Autophagy; 2023 Sep; 19(9):2464-2484. PubMed ID: 36803256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts Autophagy to Selectively Target Cancer Cells.
    O'Connell CE; Vassilev A
    Cancer Res; 2021 Jun; 81(11):2903-2917. PubMed ID: 33685990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia.
    Liu W; Bai Y; Zhou L; Jin J; Zhang M; Wang Y; Lin R; Huang W; Ren X; Ma N; Zhou F; Wang Z; Ding K
    Eur J Med Chem; 2024 Jan; 264():115974. PubMed ID: 38007910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy.
    Bao Y; Qiao Y; Choi JE; Zhang Y; Mannan R; Cheng C; He T; Zheng Y; Yu J; Gondal M; Cruz G; Grove S; Cao X; Su F; Wang R; Chang Y; Kryczek I; Cieslik M; Green MD; Zou W; Chinnaiyan AM
    Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2314416120. PubMed ID: 38011559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent inhibition of FYVE finger-containing phosphoinositide kinase induces melanosome degradation in B16F10 melanoma cells.
    Kawaguchi K; Watanabe M; Furukawa S; Koga K; Kanamori H; Ikemoto MJ; Takashima S; Maeda M; Oh-Hashi K; Hirata Y; Furuta K; Takemori H
    Mol Biol Rep; 2023 Jul; 50(7):5917-5930. PubMed ID: 37248430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of LLC0424 as a Potent and Selective
    Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
    Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
    J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
    Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
    J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer.
    Sun N; Kabir M; Lee Y; Xie L; Hu X; Velez J; Chen X; Kaniskan HÜ; Jin J
    J Med Chem; 2023 Jan; 66(1):596-610. PubMed ID: 36538511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of ZLC491 as a Potent, Selective, and Orally Bioavailable CDK12/13 PROTAC Degrader.
    Zhou L; Zhou K; Chang Y; Yang J; Fan B; Su Y; Li Z; Mannan R; Mahapatra S; Ding M; Zhou F; Huang W; Ren X; Xu J; Wang GX; Zhang J; Wang Z; Chinnaiyan AM; Ding K
    J Med Chem; 2024 Oct; 67(20):18247-18264. PubMed ID: 39388374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis.
    Sharma G; Guardia CM; Roy A; Vassilev A; Saric A; Griner LN; Marugan J; Ferrer M; Bonifacino JS; DePamphilis ML
    Autophagy; 2019 Oct; 15(10):1694-1718. PubMed ID: 30806145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors.
    Chakraborty AR; Vassilev A; Jaiswal SK; O'Connell CE; Ahrens JF; Mallon BS; Pera MF; DePamphilis ML
    Stem Cell Reports; 2022 Feb; 17(2):397-412. PubMed ID: 35063131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of LHF418 as a new potent SOS1 PROTAC degrader.
    Li H; Chai M; Chen Y; Zhou F; Ren X; Xu J; Wang J; Wang Z; Huang W
    Bioorg Med Chem; 2024 Apr; 103():117661. PubMed ID: 38489998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
    Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
    J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIKfyve inhibitor cytotoxicity requires AKT suppression and excessive cytoplasmic vacuolation.
    Ikonomov OC; Altankov G; Sbrissa D; Shisheva A
    Toxicol Appl Pharmacol; 2018 Oct; 356():151-158. PubMed ID: 30098992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of PIKfyve kinase as a target in multiple myeloma.
    de Campos CB; Zhu YX; Sepetov N; Romanov S; Bruins LA; Shi CX; Stein CK; Petit JL; Polito AN; Sharik ME; Meermeier EW; Ahmann GJ; Armenta IDL; Kruse J; Bergsagel PL; Chesi M; Meurice N; Braggio E; Stewart AK
    Haematologica; 2020 Jun; 105(6):1641-1649. PubMed ID: 31582538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
    Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
    Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer.
    Qiao Y; Choi JE; Tien JC; Simko SA; Rajendiran T; Vo JN; Delekta AD; Wang L; Xiao L; Hodge NB; Desai P; Mendoza S; Juckette K; Xu A; Soni T; Su F; Wang R; Cao X; Yu J; Kryczek I; Wang XM; Wang X; Siddiqui J; Wang Z; Bernard A; Fernandez-Salas E; Navone NM; Ellison SJ; Ding K; Eskelinen EL; Heath EI; Klionsky DJ; Zou W; Chinnaiyan AM
    Nat Cancer; 2021 Sep; 2():978-993. PubMed ID: 34738088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.